New Piperazine Compound and Use Thereof as a HCV Polymerase Inhibitor
申请人:Abe Hiroyuki
公开号:US20080081818A1
公开(公告)日:2008-04-03
The present invention relates to a compound represented by the following formula [I]
wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
Inhibitors of Hepatitis C virus, compositions and treatments using the same
申请人:AGOURON PHARMACEUTICALS, INC.
公开号:US20040229817A1
公开(公告)日:2004-11-18
The invention relates to methods of inhibiting HCV viral replication activity comprising contacting an HCV polymerase with a therapeutically effective amount of a hydroxamate MMP inhibitor, and compositions comprising the same.
NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR
申请人:Abe Hiroyuki
公开号:US20120107273A1
公开(公告)日:2012-05-03
The present invention relates to a compound represented by the following formula [I]
wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR
申请人:Japan Tobacco, Inc.
公开号:EP2009004A1
公开(公告)日:2008-12-31
The present invention relates to a compound represented by the following formula [I]
wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.